Advanced Renal Cell Carcinoma: Evaluating Triplet Strategies and Symptom-Driven First-Line Decisions

In this segment, the discussion explores the role of intensified treatment strategies in advanced renal cell carcinoma, particularly the evaluation of triplet regimens combining multiple therapeutic approaches. Dr. Elizabeth Plimack explains that, unlike other malignancies where adding more agents upfront may improve outcomes, triplet strategies in advanced renal cell carcinoma have not demonstrated clear survival benefits and may introduce additional toxicity. She highlights that the biological interactions between different treatment modalities are not fully understood, and that assumptions of synergy do not always translate into improved clinical outcomes. The conversation then shifts to practical decision-making in the first-line setting, where tumor burden, disease pace, and symptom burden play a critical role. Dr. Plimack emphasizes that in symptomatic patients, achieving rapid disease control is essential, as effective treatment can significantly improve quality of life. This segment reinforces the importance of individualized, symptom-driven treatment selection in advanced renal cell carcinoma.